Cybin (CYBN) News Today $9.91 -0.07 (-0.70%) As of 01/31/2025 04:10 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC Filings All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Cybin (OTCMKTS:CYBN) Shares Up 1.8% - Should You Buy?Cybin (OTCMKTS:CYBN) Stock Price Up 1.8% - Time to Buy?January 24, 2025 | marketbeat.comCybin: Paradigm Changing AmbitionsJanuary 20, 2025 | seekingalpha.comCybin Inc. Achieves Breakthroughs in Mental Health TreatmentJanuary 13, 2025 | tipranks.comCybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025January 9, 2025 | financialpost.comCybin Reveals Promising Results in Depression TreatmentDecember 10, 2024 | tipranks.comCybin (OTCMKTS:CYBN) Shares Down 4.3% - Here's WhyCybin (OTCMKTS:CYBN) Shares Down 4.3% - What's Next?November 28, 2024 | marketbeat.comCybin Inc. Advances in Mental Health TreatmentsNovember 25, 2024 | tipranks.comCybin (OTCMKTS:CYBN) Stock Price Up 0.2% - Should You Buy?Cybin (OTCMKTS:CYBN) Shares Up 0.2% - Still a Buy?November 6, 2024 | marketbeat.comCybin announces grant of patent in support of CYB005 phenethylamines programOctober 25, 2024 | markets.businessinsider.comBright Minds rally ends as psychedelic stocks extend volatilityOctober 16, 2024 | msn.comCybin Expands Clinical Team to Support CYB003 Phase 3 ProgramOctober 1, 2024 | finance.yahoo.comChewy executive conducted insider trading over pet insurance partnership, SEC saysSeptember 27, 2024 | ca.finance.yahoo.comClock is ticking for US recession, return of Fed's QE, says black swan fundSeptember 27, 2024 | ca.finance.yahoo.comCybin to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | finance.yahoo.comCybin Inc (R7E1.DU)August 30, 2024 | nz.finance.yahoo.comCybin Inc (R7E1.MU)August 30, 2024 | nz.finance.yahoo.comCybin (OTCMKTS:CYBN) Shares Down 0.2% Cybin (OTCMKTS:CYBN) Shares Down 0.2%August 28, 2024 | marketbeat.comBuy Rating Affirmed for Cybin Amid Advancements in Psychedelic Medicine and Strategic Regulatory ApproachesJuly 31, 2024 | markets.businessinsider.comCybin (OTCMKTS:CYBN) Trading Down 1.8%Cybin (OTCMKTS:CYBN) Shares Down 1.8%July 20, 2024 | marketbeat.comCybin (OTCMKTS:CYBN) Shares Down 2.7% Cybin (OTCMKTS:CYBN) Trading Down 2.7%June 28, 2024 | marketbeat.comCybin Provides Corporate Update and Highlights Upcoming Clinical MilestonesMay 6, 2024 | finance.yahoo.comCybin Provides Corporate Update and Highlights Upcoming Clinical MilestonesMay 6, 2024 | businesswire.comCybin Announces Publication of Research Manuscript in the Journal of Medicinal ChemistryApril 18, 2024 | businesswire.comCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive DisorderApril 16, 2024 | businesswire.comCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2024 | businesswire.comCybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 10, 2024 | businesswire.comCybin (OTCMKTS:CYBN) Trading Down 5.3%Cybin (OTCMKTS:CYBN) Shares Down 5.3%March 29, 2024 | marketbeat.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 26, 2024 | investorplace.comCybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 MillionMarch 19, 2024 | businesswire.comCybin to Present at Public Ventures Discovery Day on March 19th in DallasMarch 18, 2024 | businesswire.comCybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety DisorderMarch 15, 2024 | businesswire.comCybin’s CYB003 Shows Promise in MDD Treatment, Justifying Buy RatingMarch 14, 2024 | markets.businessinsider.comCybin to begin Phase 3 study for psychedelic drug mid-yearMarch 14, 2024 | msn.comBuy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA DesignationsMarch 14, 2024 | markets.businessinsider.comCybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program DesignMarch 14, 2024 | businesswire.comCybin Gets Breakthrough Therapy Designation For Its Psychedelic-based Therapeutic CYB003March 13, 2024 | markets.businessinsider.comCybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive DisorderMarch 13, 2024 | businesswire.comCybin to Host Conference Call and Webcast to Provide Program Update for CYB003March 12, 2024 | businesswire.com3 High-Potential Penny Stocks to Turn $1000 into $1 millionMarch 10, 2024 | investorplace.comCybin to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | businesswire.comCybin Inc.February 16, 2024 | thestreet.comCybin Reports Third Quarter Financial Results and Recent Business HighlightsFebruary 14, 2024 | finance.yahoo.comCybin Reports Third Quarter Financial Results and Recent Business HighlightsFebruary 14, 2024 | businesswire.comCybin (OTCMKTS:CYBN) Trading Up 10.8%Cybin (OTCMKTS:CYBN) Stock Price Up 10.8%February 13, 2024 | marketbeat.comCybin Announces Grant of Two Additional Patents in Japan in Support of its DMT ProgramFebruary 7, 2024 | finance.yahoo.comFDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized AnxietyJanuary 23, 2024 | msn.comCybin gets FDA clearance for Phase 2a study of psychedelic drugJanuary 23, 2024 | msn.comCybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety DisorderJanuary 23, 2024 | finance.yahoo.comBuy Rating Affirmed for Cybin Based on Advancements in Psychedelic Treatments and Optimistic ValuationJanuary 5, 2024 | markets.businessinsider.comCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog ProgramDecember 6, 2023 | finance.yahoo.com Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address CYBN Media Mentions By Week CYBN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYBN News Sentiment▼0.000.69▲Average Medical News Sentiment CYBN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYBN Articles This Week▼00▲CYBN Articles Average Week Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORIC Pharmaceuticals News Today Sana Biotechnology News Today CorMedix News Today Cronos Group News Today Avadel Pharmaceuticals News Today Septerna News Today Basilea Pharmaceutica News Today Ginkgo Bioworks News Today LENZ Therapeutics News Today Pliant Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CYBN) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYBN Stock Alerts